恒生港股通创新药指数是ETF跟踪的指数中首批"纯度"达100%的创新药指数，精准汇聚港股创新药领军 企业；中证港股通医药卫生综合指数从港股通范围内选取医药卫生行业中市值较大的50只上市公司作为 样本，覆盖创新药、医疗器械等领域。投资者可通过港股通创新药ETF易方达（159316）、港股通医药 ETF易方达（513200）等跟踪上述指数的产品，精准捕捉医药产业发展机遇。 1月30日，石药集团与阿斯利康达成总额高达185亿美元的合作，首付款12亿美元，创下中国药企对外授 权交易新纪录。2月8日，信达生物与礼来达成88.5亿美元合作，首付3.5亿美元，创新采用"端到端共 研"模式。据统计，2026年以来创新药BD合作的首付款规模，已超越2025年全年最高单季度水平，总交 易金额已达332.8亿美元，产业出海势头迅猛。 同时，龙头公司业绩预告验证了高景气度。信达生物、荣昌生物与君实生物预告2025年营业收入分别约 为110亿元、32.5亿元和25亿元，同比大幅增长45%、89%和32%，强劲的业绩增长为板块提供了坚实的 基本面支撑。 2月10日，港股医药板块全天强势领涨，截至15:15，恒生港股通创新药指数上涨2.7 ...

港股通医药ETF易方达（513200）业绩比较基准为中证港股通医药卫生综合指数收益率(使用估值汇率 折算)，管理人为易方达基金管理有限公司，基金经理为伍臣东，成立（2022-01-19）以来回报为 10.61%，近一个月回报为0.21%。 声明：市场有风险，投资需谨慎。本文基于第三方数据库自动发布，不代表新浪财经观点，任何在本文 出现的信息均只作为参考，不构成个人投资建议。如有出入请以实际公告为准。如有疑问，请联系 biz@staff.sina.com.cn。 来源：新浪基金∞工作室 2月5日，港股通医药ETF易方达（513200）跌0.73%，成交额1.35亿元。当日份额减少200.00万份，最新 份额为15.30亿份，近20个交易日份额减少1.67亿份。最新资产净值计算值为16.93亿元。 ...

2月5日，港股整体低开高走，消费板块大涨，科技与互联网板块午后反弹，南向资金全天净买入近250亿港元、创下近5个月新高。截至收盘，中证港股通消 费主题指数上涨2.8%，中证港股通互联网指数上涨0.9%，恒生港股通新经济指数、恒生科技指数均上涨0.7%，中证港股通医药卫生综合指数上涨0.5%。 Wind数据显示，截至昨日，港股通互联网ETF易方达（513040）、恒生科技ETF易方达（513010）近3个交易日分别获10.8亿元和3.3亿元资金净流入。 令日 该指数消 0. 5' 1岁指数升 技主题高度相关的、市值最大 的30只股票组成,信息技术及 0 74 可选消费行业合计占比超90% 港股通医药ETF易方达 低费率 跟踪中证港股通医药卫生综合指数 该指数由港股通范围内医疗卫 生行业中50只流动性较好、市 值较大的股票组成,医疗保健 行业权重占比超90% 港股通互联网ETF易方达 低费率 跟踪中证港股通互联网指数 该指数由港股通范围内30家互 联网龙头公司的股票组成,主 要包括信息技术、可选消费行 令日 该指数滑 每日经济新闻 ...

截至收盘，中证港股通消费主题指数下跌0.7%，中证港股通互联网指数下跌2.7%，恒生港股通新经济指数下跌3.1%，恒生科技指数下跌3.4%，中证港股通 医药卫生综合指数下跌3.5%。 华泰证券认为，本轮调整主要源于指数短期快速上行后的技术性回撤，叠加美联储偏鹰派言论引发的市场情绪扰动，而非趋势性反转信号。一季度三大核心 驱动逻辑依然稳固：流动性环境改善、内外资金共振、企业盈利预期上修。策略上宜"立足中期视角，重视空间，淡化斜率"。 该指数由港股通范围内医疗卫 生行业中50只流动性较好、市 值较大的股票组成,医疗保健 行业权重占比超90% �日 该指数消 3.5 港股通互联网ETF易方达 低费率 跟踪中证港股通互联网指数 该指数由港股通范围内30家互 联网龙头公司的股票组成,主 要包括信息技术、可选消费行 技主题高度相关的、市值最大 的30只股票组成,信息技术及 可选消费行业合计占比超90% 3.4 港股通医药ETF易方达 低费率 跟踪中证港股通医药卫生综合指数 令日 该指数污 该指数泪 每日经济新闻 ...

1. Report Industry Investment Rating - Not provided in the content 2. Core Viewpoints - The report presents several ETF strategy indices constructed by Huabao Research and tracks their performance and positions on a weekly basis, aiming to help investors convert quantitative models or subjective views into practical investment strategies [11] 3. Summary by Relevant Catalog 3.1 ETF Strategy Index Tracking - **Overall Performance**: The table shows the performance of various ETF strategy indices last week. The Huabao Research Quantitative Windmill ETF Strategy Index had the highest weekly excess return of 2.56%, while the Huabao Research SmartBeta Enhanced ETF Strategy Index had the lowest weekly excess return of -2.76% [12] 3.1.1 Huabao Research Size Rotation ETF Strategy Index - **Strategy**: It uses multi - dimensional technical indicator factors and a machine - learning model to predict the return difference between the Shenwan Large - Cap Index and the Shenwan Small - Cap Index. It outputs weekly signals to predict the strength of the indices in the next week and determines positions accordingly to obtain excess returns [13] - **Performance**: As of 2026/1/30, the excess return since 2024 was 29.34%, the excess return in the past month was 5.89%, and the excess return in the past week was - 1.86%. The index's positions include 50% in the CSI 500ETF and 50% in the CSI 1000ETF [13][17] 3.1.2 Huabao Research SmartBeta Enhanced ETF Strategy Index - **Strategy**: It uses price - volume indicators to time self - built Barra factors and maps timing signals to ETFs based on their exposure to 9 major Barra factors to achieve market - outperforming returns. The selected ETFs cover mainstream broad - based index ETFs and some style and strategy ETFs [17] - **Performance**: As of 2026/1/30, the excess return since 2024 was 20.15%, the excess return in the past month was - 2.11%, and the excess return in the past week was - 2.76%. The index's positions are mainly in several science - innovation and growth - style ETFs [17] 3.1.3 Huabao Research Quantitative Windmill ETF Strategy Index - **Strategy**: It starts from a multi - factor perspective, including the grasp of medium - to - long - term fundamentals, tracking of short - term market trends, and analysis of the behavior of various market participants. It uses valuation and crowding signals to indicate industry risks and multi - dimensionally digs out potential sectors to obtain excess returns [20] - **Performance**: As of 2026/1/30, the excess return since 2024 was 51.39%, the excess return in the past month was 6.51%, and the excess return in the past week was 2.56%. The index's positions are mainly in commodity - related and financial - related ETFs [20][25] 3.1.4 Huabao Research Quantitative Balance ETF Strategy Index - **Strategy**: It adopts a multi - factor system, including economic fundamentals, liquidity, technical analysis, and investor behavior factors, to construct a quantitative timing system for trend analysis of the equity market. It also builds a prediction model for market large - and small - cap styles to adjust the equity market position distribution and obtain excess returns through comprehensive timing and rotation [24] - **Performance**: As of 2026/1/30, the excess return since 2024 was - 10.24%, the excess return in the past month was 0.48%, and the excess return in the past week was - 0.36%. The index's positions include bonds and equity - based ETFs [24][27] 3.1.5 Huabao Research Hot - Spot Tracking ETF Strategy Index - **Strategy**: It uses strategies such as market sentiment analysis, tracking of major industry events, investor sentiment and professional opinions, policy and regulatory changes, and historical analysis to track and dig out hot - spot index target products in a timely manner, constructing an ETF portfolio that can capture market hot spots and providing short - term market trend references for investors [27] - **Performance**: As of 2026/1/30, the excess return in the past month was 6.21%, and the excess return in the past week was 3.21%. The index's positions are mainly in commodity, Hong - Kong - stock, and short - term financing ETFs [27][30] 3.1.6 Huabao Research Bond ETF Duration Strategy Index - **Strategy**: It uses bond market liquidity and price - volume indicators to screen effective timing factors and predicts bond yields through machine - learning methods. When the expected yield is below a certain threshold, it reduces the long - duration positions in the bond investment portfolio to improve long - term returns and drawdown control [30] - **Performance**: As of 2026/1/30, the excess return in the past month was 0.40%, and the excess return in the past week was 0.14%. The index's positions are mainly in bond - related ETFs [30][33]

Market Performance - The Hong Kong Stock Connect innovative drug ETF managed by E Fund (159316) experienced a strong rebound today, rising by 3.3% with a trading volume increasing to 500 million [1] Core Drivers - Liquidity expectations have improved as the U.S. December non-farm payroll data fell short of expectations, leading to heightened market anticipation for a Federal Reserve interest rate cut, with the CME "FedWatch" indicating a 40.7% probability of a rate cut in March [2] Industry Updates - Research and Development Progress: Innovent Biologics' anti-CTLA-4 monoclonal antibody "Daboshu" has been approved for market launch as the first domestic drug of its kind [2] - Business Development Activity: GSK has entered into a collaboration with AstraZeneca worth over $2 billion, setting a record for domestic clinical-stage small molecule anti-cancer drug collaborations. The total transaction amount for outbound licensing in 2025 is projected to reach $135.655 billion [2]